Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms
of patients with schizophrenia. In addition, several drugs with antioxidant properties have
been tested in clinical trials for the treatment of schizophrenia too. Whether combined
treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than
an NMDA-enhancing agent alone deserves study.